Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc a... by Melinda J. Gooderham, Michael R. Ardern‐Jones, Emma Guttman‐Yassky, Mahreen Ameen, Eric L. Simpson, Gary Chan, Pinaki Biswas, Wing S. Chiu, Melissa Watkins

Connect to this object online.

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE by Melinda J. Gooderham, MSc, MD, FRCPC, Chia-Yu Chu, MD, PhD, Ricardo Rojo, MD, Hernan Valdez, MD, Pinaki Biswas, PhD, Michael C. Cameron, MD, Claire Feeney, MD, PhD, Gerardo A. Encinas, MD, MHS, Kathleen Peeples-Lamirande, PharmD, MPH, Joseph C. Cappelleri, PhD, Daniela E. Myers, MPH, Marco DiBonaventura, PhD

Connect to this object online.